Compare CAL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | AUPH |
|---|---|---|
| Founded | 1878 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 2.1B |
| IPO Year | 1994 | 2014 |
| Metric | CAL | AUPH |
|---|---|---|
| Price | $12.43 | $16.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $15.00 | ★ $17.25 |
| AVG Volume (30 Days) | 443.9K | ★ 1.0M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | 0.42 | ★ 0.53 |
| Revenue | $85,513,000.00 | ★ $283,055,000.00 |
| Revenue This Year | $5.19 | $17.54 |
| Revenue Next Year | $2.45 | $15.74 |
| P/E Ratio | ★ $28.93 | $30.41 |
| Revenue Growth | 0.46 | ★ 20.38 |
| 52 Week Low | $8.80 | $10.34 |
| 52 Week High | $16.14 | $19.25 |
| Indicator | CAL | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 51.41 |
| Support Level | $12.02 | $14.61 |
| Resistance Level | $14.04 | $16.46 |
| Average True Range (ATR) | 0.57 | 0.47 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 18.95 | 38.28 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.